These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35370198)

  • 1. [Isoform Selectivity of HDAC Inhibitors Has a Significant Effect on PD-L1 Expression in the Triple-negative Cancer Cell Line MDA-MB-231].
    Nishino H; Hirata Y; Nagaoka Y; Uesato S
    Yakugaku Zasshi; 2022; 142(4):431-437. PubMed ID: 35370198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
    Yoon HK; Kim TH; Park S; Jung H; Quan X; Park SJ; Han J; Lee A
    Pathol Res Pract; 2018 Oct; 214(10):1626-1631. PubMed ID: 30139555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
    Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
    Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERα is a negative regulator of PD-L1 gene transcription in breast cancer.
    Liu L; Shen Y; Zhu X; Lv R; Li S; Zhang Z; Shi YG; Tan L
    Biochem Biophys Res Commun; 2018 Oct; 505(1):157-161. PubMed ID: 30241942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
    Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology.
    Hamed MM; Handoussa H; Hussein NH; Eissa RA; Abdel-Aal LK; El Tayebi HM
    Life Sci; 2021 Jul; 277():119353. PubMed ID: 33798547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].
    Yu XR; Wen QS; Xiao Y; Tang R; Li FX; Shao WF; Yu YL; Xiong JB
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 May; 38(5):561-566. PubMed ID: 29891452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; Roden AC; Hirsch FR; Wistuba II; Pusztai L
    Breast Cancer Res; 2019 Jun; 21(1):72. PubMed ID: 31196152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
    Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
    Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.
    Zhang Y; Nalawansha DA; Herath KE; Andrade R; Pflum MKH
    Mol Omics; 2021 Aug; 17(4):544-553. PubMed ID: 33885658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
    Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
    Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
    Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
    Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
    Oba T; Ono M; Matoba H; Uehara T; Hasegawa Y; Ito KI
    Breast Cancer Res Treat; 2021 Feb; 186(1):37-51. PubMed ID: 33452951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.